<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00074269</url>
  </required_header>
  <id_info>
    <org_study_id>UCSD-020815</org_study_id>
    <secondary_id>CDR0000343758</secondary_id>
    <nct_id>NCT00074269</nct_id>
  </id_info>
  <brief_title>Allogeneic Stem Cell Transplant After ATG, High-Dose Melphalan, and Fludarabine for Patients With Metastatic Breast Cancer</brief_title>
  <official_title>Pilot Study Of Allogeneic Peripheral Blood Progenitor Cell Transplantation In Patients With Chemotherapy-Refractory Or Poor-Prognosis Metastatic Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Diego</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Diego</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Giving chemotherapy, such as fludarabine and melphalan, before a donor peripheral&#xD;
      blood stem cell transplant helps stop the growth of tumor cells. It also stops the patient's&#xD;
      immune system from rejecting the donor's stem cells. The donated stem cells may replace the&#xD;
      patient's immune system and help destroy any remaining tumor cells (graft-versus-tumor&#xD;
      effect). Giving an infusion of the donor's T cells (donor lymphocyte infusion) after the&#xD;
      transplant may help increase this effect. Sometimes the transplanted cells from a donor can&#xD;
      also make an immune response against the body's normal cells. Giving antithymocyte globulin,&#xD;
      cyclosporine, and methotrexate before or after the transplant may stop this from happening.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying how well antithymocyte globulin, high-dose&#xD;
      melphalan, fludarabine, and allogeneic peripheral stem cell transplant work in treating&#xD;
      patients with metastatic adenocarcinoma of the breast.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the toxicity and tolerability of allogeneic peripheral blood stem cell&#xD;
           transplantation after a nonmyeloablative preparative regimen comprising anti-thymocyte&#xD;
           globulin, high-dose melphalan, and fludarabine in women with chemotherapy-refractory or&#xD;
           poor-prognosis metastatic adenocarcinoma of the breast.&#xD;
&#xD;
        -  Determine the ability of this preparative regimen to facilitate long-term engraftment of&#xD;
           allogeneic stem cells and lymphocytes in these patients.&#xD;
&#xD;
        -  Determine the response in measurable/evaluable disease and its temporal relationship to&#xD;
           the preparative chemotherapy used and to the onset of clinical graft-versus-host disease&#xD;
           (GVHD) in patients treated with this regimen.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the progression-free and overall survival of patients treated with this&#xD;
           regimen.&#xD;
&#xD;
        -  Determine the tumor response and its temporal relationship to administration of&#xD;
           high-dose chemotherapy and to the onset of GVHD in patients treated with this regimen.&#xD;
&#xD;
        -  Determine the frequency and durability of the induction of full donor chimerism of&#xD;
           lymphocytes in patients treated with this regimen.&#xD;
&#xD;
      OUTLINE: This is a nonrandomized, pilot study.&#xD;
&#xD;
        -  Nonmyeloablative preparative regimen: Patients receive fludarabine IV over 30 minutes on&#xD;
           days -8 to -4, anti-thymocyte globulin IV over 4 hours on days -7 to -4, and high-dose&#xD;
           melphalan IV over 30 minutes on days -3 and -2.&#xD;
&#xD;
        -  Graft-versus-host disease (GVHD) prophylaxis: Patients receive cyclosporine IV (and then&#xD;
           orally when tolerated) every 12 hours beginning on day -4 and tapered after day 42 (if&#xD;
           no GVHD occurs) or after day 90 (if grade I acute GVHD occurs). Patients also receive&#xD;
           methotrexate IV on days 1, 3, and 6.&#xD;
&#xD;
        -  Allogeneic peripheral blood stem cell transplantation (PBSCT): Patients undergo&#xD;
           allogeneic PBSCT on day 0. Patients also receive filgrastim (G-CSF) IV or subcutaneously&#xD;
           beginning on day 0 and continuing until blood counts recover.&#xD;
&#xD;
        -  Donor lymphocyte infusion (DLI): Patients who show disease progression or fail to&#xD;
           achieve full donor type T-cell chimerism (at least 90% donor derived T-cells) by the&#xD;
           90-day assessment posttransplantation, and have no evidence of active GVHD may receive&#xD;
           DLI. Patients who have unresponsive disease with no active GVHD receive subsequent DLIs&#xD;
           every 6-8 weeks.&#xD;
&#xD;
      Patients are followed at 1, 3, 6, 12, 18, 24, 30, and 36 months.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 10 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Terminated early due to poor enrollment&#xD;
  </why_stopped>
  <start_date>July 2003</start_date>
  <completion_date type="Actual">March 2008</completion_date>
  <primary_completion_date type="Actual">March 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Adverse Events</measure>
    <time_frame>5 years post transplant</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Long-term Engraftment of Allogeneic Stem Cells and Lymphocytes</measure>
    <time_frame>30 days post transplant</time_frame>
    <description>based on cell counts of ANC &gt;1000 for 3 consecutive days and platelet count of &gt;50,000</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Acute and Chronic Graft-versus-host Disease (GVHD)</measure>
    <time_frame>100 days post transplant</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival</measure>
    <time_frame>From date of transplant until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 6 months</time_frame>
    <description>Progression assessed by CT scan</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>1 year from the time of transplant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response (Partial and Complete) as Measured at 12 Months Post Allografting</measure>
    <time_frame>From date of transplant until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 12 months</time_frame>
    <description>response assessed by CT scan</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of the Induction of Full Donor Chimerism of Lymphocytes as Measured at 1 Month Post Allografting</measure>
    <time_frame>1 month post allografting</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">5</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>anti-thymocyte globulin</intervention_name>
    <arm_group_label>treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>filgrastim</intervention_name>
    <arm_group_label>treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>graft-versus-tumor induction therapy</intervention_name>
    <arm_group_label>treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>therapeutic allogeneic lymphocytes</intervention_name>
    <arm_group_label>treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclosporine</intervention_name>
    <arm_group_label>treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fludarabine phosphate</intervention_name>
    <arm_group_label>treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>melphalan</intervention_name>
    <arm_group_label>treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methotrexate</intervention_name>
    <arm_group_label>treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>peripheral blood stem cell transplantation</intervention_name>
    <arm_group_label>treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed adenocarcinoma of the breast&#xD;
&#xD;
               -  Metastatic disease&#xD;
&#xD;
          -  Meets 1 of the following criteria:&#xD;
&#xD;
               -  Chemotherapy-unresponsive disease defined as 1 of the following:&#xD;
&#xD;
                    -  Less than a partial response to 2 consecutive chemotherapy regimens that&#xD;
                       included an anthracycline and a taxane in combination or succession&#xD;
&#xD;
                    -  Progression of disease during or within 3 months of completion of a taxane,&#xD;
                       anthracycline, or platinol-based regimen&#xD;
&#xD;
               -  Histologically confirmed tumor involvement on bone marrow biopsy&#xD;
&#xD;
          -  Measurable or evaluable disease* defined as the following:&#xD;
&#xD;
               -  Bidimensionally reproducible measurable mass by physical examination,&#xD;
                  ultrasonography, radiography, CT scan, or MRI&#xD;
&#xD;
               -  Evaluable lesions apparent on clinical exam, x-ray, CT scan, or MRI which do not&#xD;
                  fit the criteria for measurability (e.g., ill-defined post-surgical masses or&#xD;
                  masses assessable in 1 dimension only)&#xD;
&#xD;
                    -  Elevation of biological markers (e.g., CA 27.29) is considered evaluable&#xD;
                       disease NOTE: *Bone lesions or pleural or peritoneal effusion alone are not&#xD;
                       considered measurable or evaluable disease&#xD;
&#xD;
          -  Appropriate candidate for allogeneic stem cell transplantation&#xD;
&#xD;
          -  No active CNS metastases&#xD;
&#xD;
          -  Available HLA-identical sibling donor&#xD;
&#xD;
               -  6/6 antigen match&#xD;
&#xD;
               -  Donor CD34 cells at least 2 times 10^6/kg recipient weight&#xD;
&#xD;
          -  Hormone receptor status:&#xD;
&#xD;
               -  Estrogen receptor negative or positive&#xD;
&#xD;
                    -  Estrogen receptor positive tumors must demonstrate progression on at least 1&#xD;
                       hormonal manipulation&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 to 60&#xD;
&#xD;
        Sex&#xD;
&#xD;
          -  Female&#xD;
&#xD;
        Menopausal status&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  Karnofsky 70-100% OR&#xD;
&#xD;
          -  ECOG 0-1&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  WBC at least 1,500/mm^3&#xD;
&#xD;
          -  Platelet count at least 30,000/mm^3&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin less than 3 times normal*&#xD;
&#xD;
          -  AST and ALT less than 3 times normal* NOTE: *Unless abnormality due to malignancy&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine no greater than 1.6 mg/dL&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  LVEF greater than 40% by echocardiography or MUGA&#xD;
&#xD;
          -  No myocardial infarction within the past 6 months&#xD;
&#xD;
        Pulmonary&#xD;
&#xD;
          -  DLCO greater than 40% of predicted&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  No serious localized or systemic infection&#xD;
&#xD;
          -  No hypersensitivity to E. coli-derived products&#xD;
&#xD;
          -  No history of non-breast malignant disease within the past 5 years except completely&#xD;
             excised nonmelanoma skin cancer or carcinoma in situ of the cervix&#xD;
&#xD;
          -  No chronic inflammatory disorder requiring concurrent glucocorticosteroids or other&#xD;
             immunosuppressive medication&#xD;
&#xD;
          -  No psychological condition or social situation that would preclude study participation&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  No concurrent glucocorticoids&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  No prior radiotherapy to an indicator lesion unless the lesion shows evidence of&#xD;
             progression after discontinuation of the therapy&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  No concurrent immunosuppressive medication&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Edward D. Ball, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Diego</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rebecca and John Moores UCSD Cancer Center</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093-0658</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <study_first_submitted>December 10, 2003</study_first_submitted>
  <study_first_submitted_qc>December 10, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 11, 2003</study_first_posted>
  <results_first_submitted>May 29, 2014</results_first_submitted>
  <results_first_submitted_qc>November 20, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 24, 2014</results_first_posted>
  <last_update_submitted>April 30, 2018</last_update_submitted>
  <last_update_submitted_qc>April 30, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 31, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, San Diego</investigator_affiliation>
    <investigator_full_name>Edward Ball</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>recurrent breast cancer</keyword>
  <keyword>stage IV breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
    <mesh_term>Antilymphocyte Serum</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The protocol recruited patients with Metastatic breast cancer for transplant after ATG, high-dose Melphalan and Fludarabine.This was a non-randomized, single arm pilot study. Patients received fludarabine IV days -8 to -4, ATG IV on days -7 to -4 and High dose Melphalan days -3 to -2. This protocol is closed to accrual as of March 2008</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Treatment</title>
          <description>anti-thymocyte globulin&#xD;
filgrastim&#xD;
graft-versus-tumor induction therapy&#xD;
therapeutic allogeneic lymphocytes&#xD;
cyclosporine&#xD;
fludarabine phosphate&#xD;
melphalan&#xD;
methotrexate&#xD;
peripheral blood stem cell transplantation</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>This is a pilot study. The original planned target accrual was 15 male or female patients age 18-60 but due to poor enrollment the study was closed to accrual early after 5 patients had been enrolled.</population>
      <group_list>
        <group group_id="B1">
          <title>Pilot Study of Allogeneic Transplant for Metastatic Breast Can</title>
          <description>anti-thymocyte globulin&#xD;
filgrastim&#xD;
graft-versus-tumor induction therapy&#xD;
therapeutic allogeneic lymphocytes&#xD;
cyclosporine&#xD;
fludarabine phosphate&#xD;
melphalan&#xD;
methotrexate&#xD;
peripheral blood stem cell transplantation</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="5"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45" lower_limit="40" upper_limit="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Adverse Events</title>
        <time_frame>5 years post transplant</time_frame>
        <population>study was closed early due to lack of accrual.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>Toxicity&#xD;
anti-thymocyte globulin&#xD;
filgrastim&#xD;
graft-versus-tumor induction therapy&#xD;
therapeutic allogeneic lymphocytes&#xD;
cyclosporine&#xD;
fludarabine phosphate&#xD;
melphalan&#xD;
methotrexate&#xD;
peripheral blood stem cell transplantation</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events</title>
          <population>study was closed early due to lack of accrual.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Long-term Engraftment of Allogeneic Stem Cells and Lymphocytes</title>
        <description>based on cell counts of ANC &gt;1000 for 3 consecutive days and platelet count of &gt;50,000</description>
        <time_frame>30 days post transplant</time_frame>
        <population>study was closed early due to lack of accrual.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>Patients treated on protocol</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Long-term Engraftment of Allogeneic Stem Cells and Lymphocytes</title>
          <description>based on cell counts of ANC &gt;1000 for 3 consecutive days and platelet count of &gt;50,000</description>
          <population>study was closed early due to lack of accrual.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Acute and Chronic Graft-versus-host Disease (GVHD)</title>
        <time_frame>100 days post transplant</time_frame>
        <population>study was closed early due to lack of accrual.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>Patients Treated Per Protocol</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Acute and Chronic Graft-versus-host Disease (GVHD)</title>
          <population>study was closed early due to lack of accrual.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression-free Survival</title>
        <description>Progression assessed by CT scan</description>
        <time_frame>From date of transplant until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 6 months</time_frame>
        <population>study was closed early due to lack of accrual.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>anti-thymocyte globulin&#xD;
filgrastim&#xD;
graft-versus-tumor induction therapy&#xD;
therapeutic allogeneic lymphocytes&#xD;
cyclosporine&#xD;
fludarabine phosphate&#xD;
melphalan&#xD;
methotrexate&#xD;
peripheral blood stem cell transplantation</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-free Survival</title>
          <description>Progression assessed by CT scan</description>
          <population>study was closed early due to lack of accrual.</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="110" lower_limit="8" upper_limit="180"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival</title>
        <time_frame>1 year from the time of transplant</time_frame>
        <population>study was closed early due to lack of accrual.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>patients treated on protocol</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival</title>
          <population>study was closed early due to lack of accrual.</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="279.4" lower_limit="98" upper_limit="373"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Response (Partial and Complete) as Measured at 12 Months Post Allografting</title>
        <description>response assessed by CT scan</description>
        <time_frame>From date of transplant until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 12 months</time_frame>
        <population>study was closed early due to lack of accrual.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>Patients treated on protocol</description>
          </group>
        </group_list>
        <measure>
          <title>Response (Partial and Complete) as Measured at 12 Months Post Allografting</title>
          <description>response assessed by CT scan</description>
          <population>study was closed early due to lack of accrual.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Frequency of the Induction of Full Donor Chimerism of Lymphocytes as Measured at 1 Month Post Allografting</title>
        <time_frame>1 month post allografting</time_frame>
        <population>study was closed early due to lack of accrual.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>Patients treated on protocol</description>
          </group>
        </group_list>
        <measure>
          <title>Frequency of the Induction of Full Donor Chimerism of Lymphocytes as Measured at 1 Month Post Allografting</title>
          <population>study was closed early due to lack of accrual.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>5 years</time_frame>
      <desc>AEs and SAEs collected on all Patients</desc>
      <group_list>
        <group group_id="E1">
          <title>Treatment</title>
          <description>The events monitored in the treatment arm of the protocol are listed below:&#xD;
incidence of Toxicity&#xD;
administration of filgrastim&#xD;
Grade of GVHD&#xD;
Initiation of graft-versus-tumor induction therapy&#xD;
Disease Status</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Hematuria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Febrile Neutropenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Pericardial Effusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Bilteral Conjunctivitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>aGVHD Gut</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>aGVHD Liver</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>ALT Elevation</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>AST Elevation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Overall GVHD</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pleural Effusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>aGVHD Skin</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Capillary Leak Syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Terminated early due to small numbers of subjects enrolled on study</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Edward Ball, Director BMT Program</name_or_title>
      <organization>UCSD</organization>
      <phone>858-822-6600</phone>
      <email>tball@ucsd.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

